Pfizer has appointed new heads of three of its major business units from 1st June.
Olivier Brandicourt (pictured) will become President and General Manager of the Emerging Markets and Established Products business units, replacing David Simmons.
John Young will replace Brandicourt as President and General Manager of the Primary Care business unit.
David Simmons is leaving Pfizer after 15 years to become CEO of global contract research organisation Pharmaceutical Product Development (PPD).
Ian Read, CEO of Pfizer, said: “We are indeed fortunate to have such a deep bench of talented leaders who can quickly assume new roles and maintain our momentum.”
Dr Brandicourt, a member of Pfizer’s Executive Leadership Team, has 20 years’ experience in the pharmaceutical industry. He has held a range of senior positions at Pfizer including medical, marketing and country management roles.
“Olivier is both a physician and a proven business leader who understands the many challenges of today’s changing industry and healthcare landscape,” said Read.
John Young will join the Executive Leadership Team. Currently Regional President of Europe and Canada for the Primary Care business unit, he has held a number of commercial positions in 25 years at Pfizer.
Read noted: “John has a deep understanding of the primary care landscape and will be a strong leader for this significant part of our business.”
Share this article: